Distinguishing Characteristics of COVID-19-Associated Mucormycosis; a Case Series.
Arch Acad Emerg Med
; 10(1): e66, 2022.
Статья
в английский
| MEDLINE | ID: covidwho-1998131
ABSTRACT
Introduction:
Since the emergence of COVID-19 pandemic, several articles have reported the co-existence of mucormycosis and COVID-19. This study aimed to distinguish the characteristics of COVID-19-associated rhinocerebral mucormycosis.Methods:
In this case series, 18 patients with COVID-19-associated rhinocerebral mucormycosis and unique clinical manifestations and outcomes, who were referred to Amiralam Hospital, a tertiary otorhinolaryngology center, Tehran, Iran, during the COVID-19 era, were reported.Results:
Eighteen patients with the mean age of 62.0 ± 11.6 (range 42 - 83) years were studied (50% males). The mean time interval between diagnosis of COVID-19 and first manifestation of mucormycosis was 15.5 ± 9.7 days. The most common presenting symptom was facial paresthesia (72.2%). Fifty percent of patients developed frozen eye. Palatal necrosis was seen in 7 cases (38.8%). Remarkably, facial paralysis was observed in 5 (27.7%) patients. Another notable clinical picture was cavernous sinus thrombosis, seen in 7 patients. We also had two cases of carotid artery occlusion. Three patients, unfortunately, passed away.Conclusion:
Rhinocerebral mucormycosis is one of the most important complications of COVID-19 patients, especially those with underlying diseases. It seems that the key to proper management of mucormycosis is early diagnosis and timely intervention, which could give a patient a chance to live more.
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Тип исследования:
Прогностическое исследование
Язык:
английский
Журнал:
Arch Acad Emerg Med
Год:
2022
Тип:
Статья
Аффилированная страна:
Aaem.v10i1.1644
Документы, близкие по теме
MEDLINE
...
LILACS
LIS